Emergent BioSolutions Inc.

Equities

EBS

US29089Q1058

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-04-12 pm EDT 5-day change 1st Jan Change
2.06 USD -5.94% Intraday chart for Emergent BioSolutions Inc. -10.04% -14.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Emergent Gets FDA's 'No Action Indicated' Status For Baltimore Bayview Manufacturing Facility MT
Emergent Biosolutions Receives NAI Status for Baltimore Bayview Manufacturing Facility CI
Sector Update: Health Care Stocks Rise Late Afternoon MT
Sector Update: Health Care Stocks Higher in Afternoon Trading MT
Emergent BioSolutions Tumbles After S&P Global Credit Downgrade MT
Emergent BioSolutions Shares Drop on S&P Downgrade DJ
North American Morning Briefing : Stock Futures -2- DJ
Benchmark Upgrades Emergent Biosolutions to Buy From Hold, Price Target is $5 MT
News Highlights : Top Company News of the Day - Thursday at 1 AM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 11 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 9 PM ET DJ
News Highlights : Top Company News of the Day - Wednesday at 7 PM ET DJ
Transcript : Emergent BioSolutions Inc., Q4 2023 Earnings Call, Mar 06, 2024
(EBS) EMERGENT BIOSOLUTIONS Sees Q1 Revenue Range $200M - $250M MT
Earnings Flash (EBS) EMERGENT BIOSOLUTIONS Reports Q4 Revenue $277M, vs. Street Est of $274M MT
Emergent BioSolutions Inc. Provides Revenue Guidance for the First Quarter and Earnings Guidance for the Full Year of 2024 CI
Emergent BioSolutions Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Emergent BioSolutions Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
North American Morning Briefing : Stock Futures -2- DJ
Sector Update: Health Care Stocks Mixed in Late Afternoon MT
Top Midday Gainers MT
Emergent appoints former Bausch + Lomb CEO to head company RE
Emergent BioSolutions Appoints Joseph C. Papa as President CI
Emergent BioSolutions Inc. Announces Changes in CEO CI
High-dose opioid reversal spray no better than lower dose in field, US study finds RE
Chart Emergent BioSolutions Inc.
More charts
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a Bioservices portfolio. Its segments include Commercial Products, MCM Products, and Services Segment. Commercial Products segment include NARCAN (naloxone HCl). MCM Products segment consists of its Anthrax - MCM, Smallpox - MCM and Other Products. Services segment consisting of its Bioservices offerings. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression. Its portfolio of Bioservices consists of three but interrelated service pillars, such as development services (process and analytical development) and drug substance manufacturing.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.06 USD
Average target price
5 USD
Spread / Average Target
+142.72%
Consensus
  1. Stock Market
  2. Equities
  3. EBS Stock
  4. News Emergent BioSolutions Inc.
  5. Sector Update: Health Care Stocks Mixed in Late Afternoon